CLSD - Clearside Biomedical

-

$undefined

N/A

(N/A)

Clearside Biomedical NASDAQ:CLSD Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company's SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications.

Location: 900 N Point Pkwy Ste 200, Georgia, 30005-8995, US | Website: clearsidebio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

102.7M

Cash

29.36M

Avg Qtr Burn

-4.778M

Short % of Float

0.26%

Insider Ownership

7.42%

Institutional Own.

26.33%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

belzupacap saratalocan (bel-sar) (AU-011) Details
Primary Choroidal Melanoma, Cancer

Phase 3

Data readout

CLS-AX Details
Wet age-related macular degeneration , Age-related macular degeneration

Big Mover™

Susp. Mover™

Phase 2b

Data readout

RGX-314 Details
Wet age-related macular degeneration , Age-related macular degeneration

Phase 2

Update

ABBV-RGX-314 Details
Diabetic retinopathy , Diabetic macular edema

Phase 2

Update